• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨肉瘤细胞系中多梳抑制复合物2频繁发生表观遗传改变。

Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines.

作者信息

Feng Helin, Tillman Heather, Wu Gang, Davidoff Andrew M, Yang Jun

机构信息

Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, People's Republic of China.

Department of Pathology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.

出版信息

Oncotarget. 2018 Jun 5;9(43):27087-27091. doi: 10.18632/oncotarget.25484.

DOI:10.18632/oncotarget.25484
PMID:29930752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6007463/
Abstract

Osteosarcoma (OS) cell lines are widely used in understanding the biological functions of cancer, identification and validation of therapeutic targets, as well as or preclinical drug screening. Here we report there is a frequent loss-of-function of polycomb repressive complex 2 (PRC2) in OS cell lines but it is rare in tumor samples based on genomic sequencing data, western blotting and immunohistochemistry analysis of H3K27me3. U2OS and 143B cell lines have a complete loss of function of PRC2 and several others have partial loss. In OS tumor tissues, only 1 out of 14 has low expression of H3K27me3. Kaplan-Meier analysis indicates that high EZH2, the component of PRC2, is associated with poor metastasis-free survival. Our observations are to raise the alarm that particular caution should be taken when using OS cell line models to study the disease, functional genomics, therapeutic target validation, drug screening, and epigenetic studies. Nevertheless, these cell lines will become useful biological tools to dissect the functions of PRC2.

摘要

骨肉瘤(OS)细胞系被广泛用于了解癌症的生物学功能、治疗靶点的鉴定与验证以及临床前药物筛选。在此我们报告,基于基因组测序数据、蛋白质免疫印迹法以及H3K27me3的免疫组织化学分析,在OS细胞系中多梳抑制复合物2(PRC2)功能缺失频繁,但在肿瘤样本中却很少见。U2OS和143B细胞系PRC2功能完全丧失,其他几个细胞系则部分丧失。在OS肿瘤组织中,14个样本中只有1个H3K27me3表达较低。Kaplan-Meier分析表明,PRC2的组成成分EZH2高表达与无转移生存期较差相关。我们的观察结果警示,在使用OS细胞系模型研究该疾病、功能基因组学、治疗靶点验证、药物筛选以及表观遗传学研究时应格外谨慎。尽管如此,这些细胞系将成为剖析PRC2功能的有用生物学工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8384/6007463/40e26c39666b/oncotarget-09-27087-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8384/6007463/40e26c39666b/oncotarget-09-27087-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8384/6007463/40e26c39666b/oncotarget-09-27087-g001.jpg

相似文献

1
Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines.骨肉瘤细胞系中多梳抑制复合物2频繁发生表观遗传改变。
Oncotarget. 2018 Jun 5;9(43):27087-27091. doi: 10.18632/oncotarget.25484.
2
The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.多梳抑制复合体通路在T细胞和自然杀伤细胞淋巴瘤中的作用:生物学及预后意义
Tumour Biol. 2016 Feb;37(2):2037-47. doi: 10.1007/s13277-015-3977-y. Epub 2015 Sep 4.
3
Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.阿替利珠单抗通过破坏多梳抑制复合物 2 的 EZH2-EED 相互作用来阻止癌细胞的增殖。
J Med Chem. 2014 Nov 26;57(22):9512-21. doi: 10.1021/jm501230c. Epub 2014 Nov 12.
4
Polycomb Repressive Complex 2 Enacts Wnt Signaling in Intestinal Homeostasis and Contributes to the Instigation of Stemness in Diseases Entailing Epithelial Hyperplasia or Neoplasia.多梳抑制复合物2在肠道稳态中发挥Wnt信号作用,并在导致上皮增生或肿瘤形成的疾病中促使干细胞特性的激发。
Stem Cells. 2017 Feb;35(2):445-457. doi: 10.1002/stem.2479. Epub 2016 Sep 13.
5
Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma.长链非编码RNA MALAT1与T和NK细胞淋巴瘤中多梳抑制复合物途径的关联
Oncotarget. 2017 May 9;8(19):31305-31317. doi: 10.18632/oncotarget.15453.
6
linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.长链非编码RNA linc-UBC1与多梳抑制复合物2(PRC2)存在物理相互作用,并作为膀胱癌淋巴结转移和生存的负性预后因素。
Biochim Biophys Acta. 2013 Oct;1832(10):1528-37. doi: 10.1016/j.bbadis.2013.05.010. Epub 2013 May 18.
7
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.水甘草酸破坏EZH2-EED复合物的相互作用并抑制PRC2依赖性癌症。
Oncotarget. 2015 May 30;6(15):13049-59. doi: 10.18632/oncotarget.3790.
8
Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.在骨肉瘤细胞中,融合结合蛋白1是EZH2抑制剂GSK343的作用靶点。
Int J Oncol. 2016 Aug;49(2):623-8. doi: 10.3892/ijo.2016.3541. Epub 2016 May 27.
9
Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.锌指增强子同源物2沉默可抑制骨肉瘤的肿瘤生长和肺转移。
Sci Rep. 2015 Aug 12;5:12999. doi: 10.1038/srep12999.
10
Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).通过抑制其衔接蛋白胚胎外胚层发育蛋白(EED)对多梳抑制复合物2(PRC2)的变构失活
J Med Chem. 2017 Mar 23;60(6):2212-2214. doi: 10.1021/acs.jmedchem.7b00287. Epub 2017 Mar 3.

引用本文的文献

1
Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases.靶向白细胞介素-11受体/增强子结合蛋白2信号轴作为骨肉瘤肺转移的治疗策略。
Discov Oncol. 2024 Jun 18;15(1):232. doi: 10.1007/s12672-024-01056-3.
2
Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.亚氨基吡啶酮与组蛋白去乙酰化酶抑制剂的新型组合通过整合应激反应在儿童实体瘤中表现出细胞毒性作用。
Am J Cancer Res. 2023 Dec 15;13(12):6241-6255. eCollection 2023.
3
(B)On(e)-cohistones and the epigenetic alterations at the root of bone cancer.

本文引用的文献

1
Whole-exome analysis in osteosarcoma to identify a personalized therapy.骨肉瘤的全外显子组分析以确定个性化治疗方案。
Oncotarget. 2017 Jul 5;8(46):80416-80428. doi: 10.18632/oncotarget.19010. eCollection 2017 Oct 6.
2
Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.骨肉瘤中 IGF 信号基因的反复突变和基因组重排的不同模式。
Nat Commun. 2017 Jun 23;8:15936. doi: 10.1038/ncomms15936.
3
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.小细胞肺癌的化学敏感性复发通过EZH2-SLFN11轴进行。
(B)单共组蛋白与骨癌根源处的表观遗传改变。
Cell Death Differ. 2025 Jan;32(1):66-77. doi: 10.1038/s41418-023-01227-9. Epub 2023 Oct 12.
4
Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent.EZH2抑制剂与YM155联合使用时具有显著的协同作用,且不依赖于H3K27me3。
Cancers (Basel). 2022 Dec 29;15(1):208. doi: 10.3390/cancers15010208.
5
Osteosarcoma mechanobiology and therapeutic targets.骨肉瘤的力学生物学和治疗靶点。
Br J Pharmacol. 2022 Jan;179(2):201-217. doi: 10.1111/bph.15713. Epub 2021 Dec 21.
6
Epigenetic rewriting at centromeric DNA repeats leads to increased chromatin accessibility and chromosomal instability.着丝粒 DNA 重复序列的表观遗传重写导致染色质可及性增加和染色体不稳定性。
Epigenetics Chromatin. 2021 Jul 28;14(1):35. doi: 10.1186/s13072-021-00410-x.
7
Surface expression of the immunotherapeutic target G in osteosarcoma depends on cell confluency.骨肉瘤中免疫治疗靶标 G 的表面表达依赖于细胞汇合度。
Cancer Rep (Hoboken). 2021 Oct;4(5):e1394. doi: 10.1002/cnr2.1394. Epub 2021 Apr 2.
8
Berberine reverses epithelial-mesenchymal transition and modulates histone methylation in osteosarcoma cells.小檗碱逆转骨肉瘤细胞的上皮-间充质转化并调节组蛋白甲基化。
Mol Biol Rep. 2020 Nov;47(11):8499-8511. doi: 10.1007/s11033-020-05892-8. Epub 2020 Oct 19.
9
Long noncoding RNAs in osteosarcoma via various signaling pathways.长链非编码 RNA 通过多种信号通路在骨肉瘤中的作用。
J Clin Lab Anal. 2020 Jun;34(6):e23317. doi: 10.1002/jcla.23317. Epub 2020 Apr 6.
10
CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.CATACOMB:一种内源性诱导基因,通过类似于 H3K27M 的机制拮抗多梳抑制复合物 2 的 H3K27 甲基化活性。
Sci Adv. 2019 Jul 3;5(7):eaax2887. doi: 10.1126/sciadv.aax2887. eCollection 2019 Jul.
Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.
4
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.组蛋白甲基转移酶EZH2的缺失会诱导急性髓系白血病对多种药物产生耐药性。
Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12.
5
EZH2 is required for mouse oocyte meiotic maturation by interacting with and stabilizing spindle assembly checkpoint protein BubRI.EZH2通过与纺锤体组装检查点蛋白BubRI相互作用并使其稳定,从而参与小鼠卵母细胞减数分裂成熟过程。
Nucleic Acids Res. 2016 Sep 19;44(16):7659-72. doi: 10.1093/nar/gkw463. Epub 2016 May 25.
6
EZH2 as a mediator of treatment resistance in melanoma.EZH2作为黑色素瘤治疗耐药的介导因子。
Pigment Cell Melanoma Res. 2016 Sep;29(5):500-7. doi: 10.1111/pcmr.12481. Epub 2016 May 25.
7
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency.骨肉瘤的外显子组测序揭示了类似于BRCA缺陷的突变特征。
Nat Commun. 2015 Dec 3;6:8940. doi: 10.1038/ncomms9940.
8
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.磷酸化介导的EZH2失活促进多发性骨髓瘤的耐药性。
J Clin Invest. 2015 Oct 26;125(12):4375-90. doi: 10.1172/JCI80325.
9
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.获得单个EZH2 D1结构域突变会导致对EZH2靶向抑制剂产生获得性耐药。
Oncotarget. 2015 Oct 20;6(32):32646-55. doi: 10.18632/oncotarget.5066.
10
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.骨肉瘤:当前治疗方法与成功的协作途径
J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24.